Melanocortin-1 receptor-specific linear peptides

    公开(公告)号:US10106578B2

    公开(公告)日:2018-10-23

    申请号:US15422850

    申请日:2017-02-02

    发明人: Wei Yang Yi-Qun Shi

    IPC分类号: C07K7/06 A61K38/00 C07K14/68

    摘要: Melanocortin receptor-specific linear peptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Y  (VI) or a pharmaceutically acceptable salt thereof, where Z, Y, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

    Melanocortin-1 Receptor-Specific Cyclic Hexapeptides
    2.
    发明申请
    Melanocortin-1 Receptor-Specific Cyclic Hexapeptides 审中-公开
    黑皮质素-1受体特异性环六肽

    公开(公告)号:US20170008931A1

    公开(公告)日:2017-01-12

    申请号:US15268761

    申请日:2016-09-19

    发明人: Wei Yang Yi-Qun Shi

    IPC分类号: C07K7/56

    摘要: Melanocortin receptor-specific cyclic hexapeptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claims, compositions and formulations including the hexapeptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

    摘要翻译: 其中R 1,R 2,R 3,R 4,R 5,R 6,R 7,R 8和R 9如权利要求中所定义,组合物和制剂包括前述式的六肽或其盐,以及预防,改善或治疗黑皮质素-1 受体介导或反应性疾病,适应症,病症和综合征。

    Melanocortin-1 Receptor-Specific Linear Peptides

    公开(公告)号:US20170145056A1

    公开(公告)日:2017-05-25

    申请号:US15422850

    申请日:2017-02-02

    发明人: Wei Yang Yi-Qun Shi

    IPC分类号: C07K7/06

    摘要: Melanocortin receptor-specific linear peptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Y   (VI) or a pharmaceutically acceptable salt thereof, where Z, Y, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.